tbuckley/cabot-search huggingface dataset:
Association of Fat Grafting With Patient-Reported Outcomes in Postmastectomy Breast Reconstruction
Authors: Katelyn G. Bennett, Ji Qi, Hyungjin M. Kim, Jennifer B. Hamill, Edwin G. Wilkins, Babak J. Mehrara, Jeffrey H. Kozlow
Journal: JAMA Surgery (2017)

Fat grafting has proven to be a useful adjunct to breast reconstruction for the treatment of contour irregularities and volume deficits, but the proposed US Food and Drug Administration regulations may severely limit the ability of plastic surgeons to continue its use in this clinical context.To determine whether fat grafting is associated with patient-reported outcomes (PROs) in patients undergoing breast reconstruction.A longitudinal, multicenter, prospective cohort study was conducted between February 1, 2012, and July 31, 2016, at the 11 sites associated with the Mastectomy Reconstruction Outcomes Consortium Study. Eligible patients included women 18 years or older presenting for breast reconstruction after mastectomy with 2 years or more of follow-up. All primary procedure types (implant based and flap based) were eligible. Patients were excluded if they had not completed breast mound reconstruction by 1 year after starting reconstruction.Fat grafting as an adjunct to breast mound reconstruction.Primary end points were patient-reported outcome measures as assessed by the validated BREAST-Q survey, with higher scores on a 0- to 100-point scale indicating better health-related quality of life. Survey subscales included breast satisfaction, as well as psychosocial, physical, and sexual well-being. Patient-reported outcomes were compared between those who received and did not receive fat grafting.A total of 2048 women were included (mean [SD] age, 49.4 [10] years), with 165 (8.1%) undergoing fat grafting between years 1 and 2. One year postoperatively, patients who later underwent fat grafting reported significantly lower breast satisfaction (adjusted mean difference [AMD], -4.74; 95% CI, -8.21 to -1.28; P = .008), psychosocial well-being (AMD, -3.87; 95% CI, -7.33 to -0.40; P = .03), and sexual well-being (AMD, -5.59; 95% CI, -9.70 to -1.47; P = .008), compared with those who did not receive subsequent fat grafting. Following the procedure, the fat-grafted cohort reported similar breast satisfaction (AMD, -0.68; 95% CI, -4.42 to 3.06; P = .72), psychosocial well-being (AMD, -0.59; 95% CI, -3.92 to 2.74; P = .73), and sexual well-being (AMD, -2.94; 95% CI, -7.01 to 1.12; P = .15) 2 years postoperatively.Fat grafting may improve breast satisfaction, psychosocial well-being, and sexual well-being in patients undergoing breast reconstruction.
Studies in Relation to Malaria.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Downstaging with neoadjuvant chemotherapy in locally advanced gall bladder cancers, improves outcomes
Authors: Vikas Ostwal, Anup Toshniwal, Vikram Chaudhari, Arvind Sahu, Bhawna Sirohi, Nitin Shetty, Shraddha Patkar, Hollis Dsouza, Anant Ramaswamy, Shailesh Shrikhande, Mahesh Goel
Journal: Annals of Oncology (2017)
Erratum: Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of Myc overexpression (Cancer Research (June 1, 2006) 66 (5565-5573))
Authors: K. Toyo-Oka, T. J. Bowen, S. Hirotsune, Z. Li, S. Jain, S. Ota, Laure Escoubet-Lozach, Ivan Garcia-Bassets, J. Lozach, M. G. Rosenfeld, Christopher K. Glass, R. Eisenman, B. Ren, P. Hurlin, A. Wynshaw-Boris
Journal: Cancer Research (2006)
Effects of erybuline/capecitabine (EC) treatment in very elderly women (VEW) with MBC.
Authors: Antonio Russo, Viviana Bazan, Ignazio Ugo Carreca, Giuseppe Cicero, Anna Paola Carreca
Journal: Journal of Clinical Oncology (2017)

e12508 Background: Eribuline mesylate, is widely prescribed for MBC pts alone or in combination with Capecitabine in patients pretreated with at least 1-2 lines of chemotherapy, including anthracyclines and taxanes (A&amp;T). Elderly Patients (EP) develop rapid and sometimes fatal toxicity during treatments due to pharmacokinetic features of these drugs.A combination schedule (E+C) to evaluate its suitability for VEW with MBC patients ,was used in this study. Methods: Treatment plan: E 0.96 mg/sqm IV on d1 every 21d - C 900 mg/sqm bid d1-14 every 28d (Dose-adjustement if necessary was according to Kintzel-Dorr’s formula for elderly), schedule administration continued until progression or intolerable toxicity . Eligibility criteria: histologically confirmed diagnosis of BC, 1 or more measurable lesion,(bone or visceral ) not brain mts, age &gt; 75 years, failure of previous treatment with A or T , Comprehensive Geriatric Assessment evaluation (CGA) permissive for chemotherapy, adequate renal (CCl evaluation), bone marrow and liver function. Charlson's Score Comorbidity Scale was also considered. Evaluations tools: Clinical Benefit (CB) as Stable Disease + Objective Response Rates according to ESMO CB scale v.2a, Toxicity Profile using CTCAE v3.0 Criteria and Quality of Life (QoL) score through EORTC QLQ-C30 questionnaires V.3. Results: From 2014 jan to 2016 dec ,39 metastatic VEW, mean age 83.5 were treated and 37 are still under maintenance therapy (2 pts discontinued treatment for personal reasons). A total of 659 cycles were delivered to the 37 pts without any G4 toxicity. No delay in therapy delivery was needed. QoL score shows no worsening with improvement in about 79% after treatment in comparison with baseline. Clinical Benefit was evaluated about 80%. Conclusions: A further period of monitoring allowed to confirm our previous report in this setting with this combination schedule. It appears more fit with comorbidity or frailty than other chemotherapy regimens for MBC. The analysis of preliminary data shows a non-inferiority vs other usual treatments ,more suitability for very elderly women. An enlarged polycentric study is ongoing in order to confirm these outcomes.
Abstract 072: Protein Kinase A prevents cardiomyocyte hypertrophy through abhydrolase domain containing 5 (ABHD5)-mediated proteolysis of Histone deacetylase 4(HDAC4)
Authors: Zegeye H Jebessa, Barbara Worst, Hugo A Katus, Johannes Backs
Journal: Circulation Research (2013)

Histone deacetylase 4 (HDAC4) regulates numerous gene expression programs through its signal-dependent repression of the transcription factor myocyte enhancer factor 2 (MEF2). Calcium/calmodulin-dependent protein kinase II (CaMKII) signaling promotes pathological cardiac remodeling by phosphorylating HDAC4, with consequent stimulation of MEF2 activity. Recently, we described a novel mechanism whereby protein kinase A (PKA) overcomes CaMKII-mediated activation of MEF2 by regulated proteolysis of HDAC4. PKA induces the generation of an N-terminal HDAC4 cleavage product (HDAC4-NT). HDAC4-NT inhibits MEF2 activity, thereby antagonizing the pro-hypertrophic actions of CaMKII signaling. However, the individual protease mediating HDAC4 proteolysis remains unknown. Using a number of group specific chemical protease inhibitors, we found that the PKA-dependent HDAC4 protease belongs to the family of serine proteases. To further identify the individual serine protease, we screened a human serine protease siRNA library and found abhydrolase domain containing 5 (ABHD5) to be required for PKA-induced HDAC4 proteolysis. The screening result was validated using three different siRNAs. Remarkably, forced adenoviral expression of ABHD5 led to robust production of HDAC4-NT in isolated neonatal rat ventricular myocytes (NRVMs) even in the absence of PKA. Furthermore, adenoviral expression of ABHD5 in NRVMs inhibited MEF2 transcriptional activity and attenuated cardiomyocyte hypertrophy. Interestingly, ABHD5 was initially described to be involved in lipid metabolism. Taken together, we show that ABHD5 is required for PKA-dependent HDAC4 proteolysis and sufficient for HDAC4-NT production as well as inhibition of cardiomyocyte hypertrophy. These data imply a so far unknown link between lipid metabolism and epigenetic regulation of cardioprotection.
A phase II trial of temsirolimus plus low-dose weekly carboplatin and paclitaxel for recurrent/metastatic HNSCC.
Authors: Matthew G. Fury, Han Xiao, Shrujal S. Baxi, Eric Jeffrey Sherman, Stephanie Smith-Marrone, Alan Loh Ho, Camelia S. Sima, Obiageli Ginka Nwankwo, Sofia Haque, Nora Katabi, David G. Pfister
Journal: Journal of Clinical Oncology (2014)

6019^ Background: The PI3K/mTOR pathway is commonly altered in HNSCC, but single agent activity of mTOR inhibitors is modest. Following up on encouraging results of a phase I study of temsirolimus + low dose chemotherapy (PMID 22644799), we launched this prospective phase II study. Methods: This was a nonrandomized, prospective, phase II study at MSKCC main campus and regional network affiliates. Eligible patients (≤ 2 prior regimens for R/M disease) received paclitaxel (80 mg/m2) + carboplatin (AUC 1.5) + temsirolimus (25 mg flat dose) by vein, on days 1 and 8 of a 21 day cycle for up to 6 cycles. After 6 cycles, patients without progressive disease had the option for temsirolimus monotherapy. The primary endpoint was objective response rate, as assessed by RECIST 1.0. Results: Between 1/11/2012 and 5/15/2013, 30 eligible subjects were enrolled (22 M/8 F): median age 59 (range, 30 to 85 years), median KPS 80 (range, 70 to 90). 15 patients had received at least one prior systemic therapy regimen for R/M disease. Primary tumor sites were larynx (10), oropharynx (9; HPV ISH status- 6 positive, 2 negative, 1 not done), oral cavity (8), neck node with occult primary (2), and hypopharynx (1). 17 patients had tobacco history of > 10 pack-years. The most common ≥ grade 3 AEs were lymphopenia (56%), leukopenia (37%), and neutropenia, dysphagia, and low hemoglobin (each 20%). The overall radiologic response rate was 43% (13/30) with 1 CR, 10 confirmed PRs, and 2 unconfirmed PRs (Figure 1). Overall survival was 12.9 months (95% CI, 12.3 – 13.5). Correlative studies on pre-treatment pathology samples are in progress to evaluate if p-eIF4E:p-4EBP-1 ratio is associated with efficacy. Conclusions: This low dose weekly chemotherapy regimen demonstrates clinical activity comparable to that of standard high dose combination chemotherapy regimens, and was well tolerated after first line therapy. Acknowledgment: This study was approved and funded by the National Comprehensive Cancer Network (NCCN) from generous research support provided by Pfizer. Clinical trial information: NCT01016769.
A Quantitative Assay of In Vivo Cleavage of Von Willebrand Factor By ADAMTS13 Reveals Excessive Cleavage in Type 2B Von Willebrand Disease and Diminished Cleavage in Thrombotic Thrombocytopenic Purpura
Authors: Xiaoyun Fu, Mallory N. Pahl, Yi Wang, Barbara A. Konkle, Junmei Chen, Jose A Lopez
Journal: Blood (2016)
Abstract 3613: Anemia as an Independent Predictor of Elevated Pro-BNP Levels in Patients without Evidence of Heart Failure and Normal Renal Function
Authors: Salman A Haq, Mohammad E Alam, Larry Bernstein, Lesan T Banko, Barry I Saul, Leonard Y Lee, Terrence J Sacchi, John F Heitner
Journal: Circulation (2006)
Neonate With Cutaneous Vesicles and Respiratory Distress
Authors: Kate E. Oberlin, Erin X. Wei, George W. Elgart
Journal: JAMA Pediatrics (2017)

A 3-day-old premature male infant, born at 26 weeks’ gestational age, presented to the dermatology department with multiple, grouped vesicles and punched-out ulcerations on the scalp, axilla, extremities, and scrotum. What is your diagnosis?
Abstract 311: Single-Dose Isoproterenol does not Depress Cardiac Function in Mice
Authors: Markus Wallner, Jason M Duran, Sarah Koller, Sadia Mohsin, Steffen Lis, Thomas E Sharp, Remus M Berretta, Steven R Houser
Journal: Circulation Research (2015)

Rationale: Myocardial injury after repeated or continuous administration of isoproterenol (ISO) in preclinical models has been widely described in the literature by our lab and others. Recent controversial reports using a one-time dose of ISO, to mimic a Takotsubo-like cardiomyopathy, demonstrated pronounced and reversible depression of cardiac function at one-week post injection with widespread myocyte death followed by robust myocardial regeneration and recovery of cardiac function. Hypothesis: Single-dose ISO does not produce depression of cardiac function Methods and Results: C57Bl/6 mice were given a single subcutaneous injection of vehicle (saline) or 5, 200, or 300 mg/kg of ISO. Cardiac function was measured using transthoracic echocardiography with cardiac strain analysis at baseline prior to ISO injection and after 1, 7, 14, and 28 days post-injection. Animals were sacrificed after 1, 7, and 28 days post-injection for evaluation of gross heart weight (HW), HW/body weight (BW) and HW/tibia length (TL). Left ventricular (LV) functional measurements revealed no significant differences in global systolic function (ejection fraction and fractional shortening) between vehicle- or ISO-treated animals at any concentration. Additionally, no significant differences were detected between vehicle- or ISO-treated animals in any cardiac dimensions measured by echocardiography (LV cross-sectional area, internal diameter, end-diastolic or end-systolic volumes) or in gross HW, HW/BW or HW/TL. LV global cardiac strain was also not significantly different between vehicle and ISO-treated animals at any time point. When apical regions of the LV endocardium (the area most predominantly affected by Takotsubo cardiomyopathy) were specifically examined using strain analysis, no significant differences could be detected between vehicle and ISO-treated animals at any time point. Conclusion: Single-dose ISO injury in a mouse model does not produce any depression of cardiac function at 1 week post injection.
Assessing Depression Among New Fathers
Authors: Eric Laurent, Renzo Bianchi
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Information without wisdom
Authors: Iona Heath
Journal: BMJ (2017)

This is the dystopian future: health related data are to be harvested from a huge variety of digital sources, including biometric sensors attached to individual bodies. This information is then fed back to the supposedly autonomous person and can be used to trigger algorithms and offer possibilities for remedial interventions.1

Technology is remarkably seductive and may delude us into thinking that the human condition is changing faster than it really is. Big data, biometric sensors, and the vaunted promise of e-health have undoubted contributions to make to contemporary healthcare but fall far short of delivering the moral core of medicine that has always been the relief …
Tissue Factor Pathway Inhibitor Mediates Attenuation of Tissue Factor-Stimulated Thrombin Generation in Early Onset Preeclampsia
Authors: Karl Egan, Hugh O'Connor, Barry Kevane, Fergal Malone, Amani Al Zadjali, Sharon Cooley, Cathy Monteith, Patricia Maguire, Paulina Szklanna, Seamus Allen, Naomi McCallion, Fionnuala Ní Áinle
Journal: Blood (2016)
Back to the drawing board?
Authors: H. Snook
Journal: BMJ (1995)

The audience dumped their bags, sat down, and tried to look as bored as possible. The teachers stood by the sidelines, gazing at the unorthodox scenery. They knew no more about what My Friend Willy was going to be like than I did. All I had been told--and, I suppose, all they had been told--was that it was a sex education play. A sex education play with believable characters and a true to life storyline. Disappointingly, it turned out to be crudely sketched, oversimplified, and unlikely to educate anybody.

My Friend Willy (yes, you get the joke) centres on three 15 year old and 16 year old students and their experiences. There is Willy, successful and supposedly …
Treatment Beyond Progression With Immune Checkpoint Inhibitors—Known Unknowns
Authors: Gideon M. Blumenthal, Marc R. Theoret, Richard Pazdur
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Plasma asymmetrical-dimethyl-arginine affects eNOS vascular superoxide radical production and nitric oxide bioavailability in human arteries and veins
Authors: C A Antoniades, C Shirodaria, P Leeson, D Tousoulis, A Antonopoulos, C Ratnatunga, R Pillai, T Van-Assche, C Stefanadis, K Channon
Journal: Journal of the American College of Cardiology (2008)
Posters
Authors: Laurence Delhaès, A. Jourdain, M. d'Almeida-Fourquet, Emilie Fréalle, Sylvie Leroy, Claudine Pinel, Bérengère Coltey, Loïc Favennec, S. Dominique, O. Vagner, Annlyse Fanton, Jean-Philippe Bouchara, Christine Person, Isabelle Durand-Joly, Guy-André Loeuille, Philippe Domblides, Isabelle Accoceberry, A. Farce, P. Chavatte, Benoit Wallaert
Journal: Clinical Microbiology and Infection (2011)
BMA annual meeting: Social media abuse leads to new BMA code of conduct
Authors: Rebecca Coombes
Journal: BMJ (2017)

A new code of conduct for BMA members will be introduced this week in the wake of “horrendous” abuse faced by elected representatives on social media during the junior doctors’ strike last year.

Delegates, who approved the new code of conduct on Monday at the BMA’s annual representative meeting in Bournemouth, heard from Ellen McCourt of her experiences as chair of the association’s Junior Doctors Committee (JDC) last year.1

“There were statements like, ‘You are too ugly to be chair of the JDC,’ or, ‘Who put a hippopotamus on the TV?’” said McCourt. “Elected BMA representatives used the most obnoxious language in a sustained, personal, and misogynistic campaign.”

Jeeves Wijesuriya, chair of the JDC, said that the abuse had deterred other members from taking up elected roles. “In the last 16 months the JDC has had six different combinations of chair and interim chair. For the first time this year we had no candidate for chair. Why? The level of personal abuse—not professional scrutiny but attacks based on gender, appearance, and made-up nonsense,” he said. …
Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment
Authors: Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner, Ben C. Creelan
Journal: Journal for ImmunoTherapy of Cancer (2017)

The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur.We describe an autoimmune polymyositis following a partial response to combination tremelimumab and durvalumab for the treatment of recurrent lung adenocarcinoma. Radiography revealed significant reduction in all metastases; however, the patient developed progressive neuromuscular hypoventilation due to lymphocytic destruction of the diaphragmatic musculature. Serologic testing revealed a low level of de novo circulating antibodies against striated muscle fiber. Immunohistochemistry revealed type II muscle fiber atrophy with a mixed CD8+ and CD4+ lymphocyte infiltrate, indicative of inflammatory myopathy.This case supports the hypothesis that muscle tissue is a target for lymphocytic infiltration in immune checkpoint inhibitor-associated polymyositis. Further insights into the autoimmune mechanism of PM will hopefully contribute to the prevention and treatment of this phenomenon.
Microneedle patch for flu vaccination proves successful in human clinical trial
Authors: Jacqui Wise
Journal: BMJ (2017)

An influenza vaccine delivered by a dissolvable microneedle patch can produce robust immune responses and be successfully self applied, a human trial published in the Lancet has shown.1

The patch, which looks like a small sticking plaster or Band-Aid, has 100 water soluble microneedles that dissolve within minutes of insertion into the skin, releasing the vaccine. The patch can then be peeled away and discarded.

The phase I study found that the microneedle patch was stable for one year at 40°C, meaning that it could be distributed and stored outside the cold chain and potentially stored on a pharmacy …
FIT test-systems for mega-scale gut microbiome testing
Authors: Dita Gudra, Davids Fridmanis, Janis Klovins, Girts Skenders, Ivars Silamikelis, Ilze Radovica-Spalvina, Raitis Peculis, Ineta Kalnina, Ilze Elbere, Rolf Hultcrantz, Marcis Leja, Lars Engstrand
Journal: Annals of Oncology (2017)
Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review
Authors: P. Loubet, C. Burdet, W. Vindrios, N. Grall, M. Wolff, Y. Yazdanpanah, A. Andremont, X. Duval, F.-X. Lescure
Journal: Clinical Microbiology and Infection (2017)